key: cord-0328807-wjmqpl57 authors: Mosier, Jarrod M; Sammani, Saad; Kempf, Carrie; Unger, Evan; Garcia, Joe GN title: The impact of intravenous dodecafluoropentane on a murine model of acute lung injury date: 2020-08-17 journal: bioRxiv DOI: 10.1101/2020.08.17.253658 sha: 59cb28c185c23948182e21e4598073cc4569e20a doc_id: 328807 cord_uid: wjmqpl57 Acute hypoxemic respiratory failure presents therapeutic challenges due to ventilation/perfusion mismatch and shunt. The goal of management strategies is to improve arterial oxygenation, however each management strategy presents risk to patients from iatrogenic injury. Intravenous oxygen therapeutics present an appealing option to improve arterial oxygenation without these risks. We used a two-hit murine model of acute lung injury to evaluate the effect of intravenous dodecafluoropentane (NanO2) on oxygen saturation and bronchoalveolar lavage cell count and protein. Mice were given intratracheal lipopolysaccharide and 20 hours later were intubated and ventilated with high tidal volumes. NanO2 was given by bolus injection at the initiation of mechanical ventilation and again at 2 hours, while oxygen saturation was measured every 15 minutes. At the conclusion of the experiment (4 hours), a bronchoalveolar lavage was performed. There was no difference in mean O2 saturation at time zero, however the difference between the mean O2 saturation immediately prior to injection and the mean first O2 saturation after injection in the control saline group were 91% and 83%, mean difference −7.5%; whereas mean O2 saturation in the NanO2 treated group rose from 89% to 91%, mean difference +2.5%, net difference 10% [95% CI: 2.7,17.3], p=0.01). There was a statistically significant difference in cell count, but not protein, on the bronchoalveolar lavage analysis. These data show that NanO2 rapidly improves oxygen saturation in a two-hit model of acute lung injury, and shows potential as an intravenous oxygen therapeutic in the management in acute hypoxemic respiratory failure. Dodecafluoropentane emulsion [NanO 2 TM , NuvOx Pharma (Tucson, AZ)] is one 78 such promising perfluorocarbon. The molecular characteristics of NanO 2, comprised of 79 2% weight/volume dodecafluoropentane emulsion (DDFPe)(9) make it highly effective at 80 oxygen delivery at extremely low doses,(10) and an ideal intravenous agent for O 2 delivery. 81 In this study, we aimed to evaluate the potential of NanO 2 to improve oxygenation in 82 conditions of low V/Q mismatch and high intrapulmonary shunt by using a preclinical 83 model of acute lung injury and measuring the difference in mean oxygen saturation after 84 injection of NanO 2 or saline and differences in BAL cell count and protein. We used an established two-hit mouse model of acute lung injury for this Acute hypoxemic respiratory failure is one of the most common reasons for 57 admission in critically ill patients. The underlying ventilator/perfusion (V/Q) mismatch and 58 intrapulmonary shunt presents increased risk to patients when using noninvasive 59 ventilatory strategies, during preoxygenation for intubation, or during mechanical 60 ventilation. Noninvasive strategies (1) suffer high failure rates, which imposes 61 disproportionately higher mortality mediated, particularly with NIPPV, by patient-self-62 induced lung injury (P-SILI).(2, 3) Intubation in these patients comes with high risk of 63 rapid desaturation Mechanical ventilation carries the risk of ventilator-induced lung injury (VILI) from injurious High-Flow Oxygen Therapy Concepts: 199 Time to Standardize Nomenclature and Avoid Confusion Failure of Noninvasive Ventilation for De Novo Acute Hypoxemic Respiratory Failure: Role of Tidal 203 Volume Physiological Comparison of High-Flow Nasal Cannula and Helmet Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure. American journal of respiratory and critical care 207 medicine Cardiac 209 Arrest and Mortality Related to Intubation Procedure in Critically Ill Adult Patients: A 210 Multicenter Cohort Study Physiologically difficult airway in critically ill patients: winning the race 212 between haemoglobin desaturation and tracheal intubation Partial liquid ventilation for 218 preventing death and morbidity in adults with acute lung injury and acute respiratory distress 219 syndrome. Cochrane database of systematic reviews Human 221 pharmacokinetics of a perfluorocarbon ultrasound contrast agent evaluated with gas 222 chromatography The theory and application of intravascular 224 microbubbles as an ultra-effective means of transporting oxygen and other gases Differential 227 and opposing effects of imatinib on LPS-and ventilator-induced lung injury. American journal of 228 physiology Lung cellular and molecular physiology Dodecafluoropentane Emulsion (DDFPe) Decreases Stroke Size and Improves Neurological 231 Scores in a Permanent Occlusion Rat Stroke Model Dodecafluoropentane Emulsion Extends Window for tPA Therapy in a Rabbit Stroke Model Progress in 239 dodecafluoropentane emulsion as a neuroprotective agent in a rabbit stroke model Dodecafluoropentane 242 emulsion elicits cardiac protection against myocardial infarction through an ATP-Sensitive K+ 243 channel dependent mechanism Hypoxia due to shunts in pig lung 245 treated with O2 and fluorocarbon-derived intravascular microbubbles. Artificial cells, blood 246 substitutes, and immobilization biotechnology microbubbles protect against fatal anemia in rats. Artificial cells, blood substitutes, and 249 immobilization biotechnology Dodecafluoropentane Emulsion in Acute Ischemic Stroke: A Phase Ib/II Randomized and 252 Controlled Dose-Escalation Trial Tracheal Intubation in the 255 Critically Ill: Where We Came From and Where We Should Go. American journal of respiratory 256 and critical care medicine